News and Events

pattern of DNA methylation in a meningioma tumor

New way to classify meningioma brain tumors suggests potential treatments

Two studies have found a new way to classify meningioma, a type of tumor that forms in the outer covering of the brain. Kenneth Aldape, M.D., Chief and Senior Investigator of the Laboratory of Pathology, speaks about how the new grouping system may help predict whether a patient’s tumor will grow back after treatment and may reveal new treatment possibilities.

2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology

Registration and abstract submission is now open for the 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology.

This two-day national conference provides a venue for scientists world-wide to exchange the latest information on the immunotherapy of cancer. We are looking forward to an exciting forum for discussion and debate on the current understanding of cancer and immunology and immunotherapy.

Sessions include:

CAR T-Cell Based Immunotherapies
Cell Therapy for Solid Epithelial Cancers
Principles of Checkpoint Modulators
Clinical Applications of Checkpoint Modulators
Microbiome and Immunotherapy
Factors Influencing the Success of Immunotherapy
Innovative Approaches to Immunotherapy

Clinical trial researches immunotherapy for recurrent thymoma and thymic carcinoma

A clinical trial led by Arun Rajan, M.D., Senior Clinician in the Thoracic and GI Malignancies Branch, is researching treatments, including immunotherapy, for recurrent thymoma and thymic carcinoma.

ALIGNED for Pride

June is Pride Month, a celebration of LGBTQIA+ folks that dates back to the 1969 Stonewall Uprising. Pride is a time to celebrate our family, friends and colleagues in the LGBTQIA+ community. For this edition of Aligned, I asked a few friends and colleagues to tell me what Pride means to them.

Sung-Yun Pai selected for Hedwig van Ameringen Executive Leadership in Academic Medicine® (ELAM) Program

Sung-Yun Pai, M.D., Chief of the Immune Deficiency Cellular Therapy Program, was selected for the Hedwig van Ameringen Executive Leadership in Academic Medicine® (ELAM) Program for Women at Drexel University College of Medicine. The ELAM® program is dedicated to developing leadership and management skills in healthcare and is designed for senior-level women leaders interested in advancing hospitals and healthcare systems.

Celebrating Asian American, Native Hawaiian, and Pacific Islander Heritage Month: A Conversation with Lilian Yang, M.B.A.

Lilian Yang, M.B.A., is the Senior Branch Manager in the Neuro-Oncology Branch (NOB). She is originally from Hawaii and identifies as Chinese American. In this Asian American, Native Hawaiian, and Pacific Islander Heritage Month Q&A, she talks to us about the many places she has lived, some valuable business school advice, and the need for Asian representation in leadership roles.

Celebrating AANHPI Heritage Month: A Conversation with Suresh Ambudkar, Ph.D.

Suresh V. Ambudkar, Ph.D., is a Senior Investigator and the Deputy Chief of the Laboratory of Cell Biology. For this Asian American, Native Hawaiian, and Pacific Islander Heritage Month Q&A, he answers some questions about his academic, research and personal journey immigrating from India to the United States.

Clinical trial researching immunotherapy for B-cell lymphoma

A clinical trial led by Mark Roschewski, M.D., Senior Clinician in the Lymphoid Malignancies Branch, is researching immunotherapy for indolent B-cell lymphoma, a cancer of white blood cells that frequently relapses.

Celebrating AANHPI Heritage Month: A Conversation with Fatima Karzai, M.D.

Fatima Karzai, M.D., Associate Research Physician and Clinical Director in the Genitourinary Malignancies Branch, is a clinical researcher at CCR. She is originally from Afghanistan. For this Asian American, Native Hawaiian, Pacific Islander Heritage Month Q&A, she discussed her research interests and how her background as an Afghan American woman influences her work today.

Machine learning reveals rules of T cell activation

CCR and McGill University scientists have used machine learning to build models that can predict T cell responses against tumors.

Breadcrumb